RecruitingNot ApplicableNCT07340008

Analgosedation With Ketamine, Nalbuphine, or Dexmedetomidine for Suture Removal in Children After Cleft Surgery

Comparison of Intramuscular Ketamine and Intranasal Nalbuphine and Dexmedetomidine for Analgosedation in Children Undergoing Suture Removal After Surgery for Congenital Clefts of the Palate, Alveolar Ridge, and Lip


Sponsor

University Medical Centre Ljubljana

Enrollment

60 participants

Start Date

Sep 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This prospective, randomized study is designed to compare the efficacy and safety of three sedative-analgesic agents-intramuscular ketamine, intranasal nalbuphine, and intranasal dexmedetomidine-for procedural sedation in children undergoing suture removal following cleft palate, alveolar ridge, or lip surgery. The study will include 60 children aged 6 months to 3 years, randomly assigned to one of three intervention groups. The primary objectives are to compare time to achieve adequate sedation (Modified Ramsay Sedation Scale 2-3), surgeon-rated ease of surgical procedure, and time to discharge readiness (Modified Aldrete Score ≥9). Secondary outcomes include baseline child behavior, response to drug administration, depth of sedation, response to separation from parents, and parental satisfaction, as well as monitoring of perioperative complications and vital signs. All study medications are approved and commonly used in pediatric anesthesia. The trial will be conducted using non-invasive monitoring, with intravenous access established only in case of emergency interventions. Findings from this study are expected to provide evidence to optimize pediatric sedation protocols for minor surgical procedures.


Eligibility

Min Age: 6 MonthsMax Age: 3 Years

Inclusion Criteria6

  • Age 6 months to 3 years
  • Scheduled for suture removal after surgery for congenital cleft of the palate, alveolar ridge, or lip
  • American Society of Anesthesiologists (ASA) physical status I or II
  • Written informed consent obtained from parents or legal guardians
  • Slovene-speaking family to ensure understanding and compliance
  • No contraindications to the use of study medications

Exclusion Criteria6

  • Known allergy or hypersensitivity to ketamine, nalbuphine, or dexmedetomidine
  • ASA physical status greater than II
  • Significant neurological, psychiatric, or respiratory disorder
  • Active or recent upper respiratory tract infection
  • Refusal of parental or guardian consent
  • Developmental disorder affecting communication or cooperation

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGketamine

Intramuscular administration of Ketamine at 4 mg/kg body weight for analgosedation during suture removal in children after surgery for congenital clefts. Glycopyrrolate 4 mcg/kg will be co-administered to reduce salivation.

DRUGNalbuphine

Intranasal administration of Nalbuphine at 0.5 mg/kg body weight via mucosal atomizer device (MAD) for analgosedation during suture removal after cleft surgery in children.

DRUGDexmedetomidine

Intranasal administration of Dexmedetomidine at 3 mcg/kg body weight via mucosal atomizer device (MAD) for analgosedation during suture removal after cleft surgery in children.


Locations(1)

Department of Maxillofacial and Oral Surgery, University Medical Centre Ljubljana

Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07340008


Related Trials